Immunotherapy in Lung Cancer | Specialty

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Chemoimmunotherapy Combos, Adjuvant Approaches and Bispecifics Are Among Exciting Advances in Lung Cancer

October 19th 2021

The availability of chemoimmunotherapy combinations and targeted agents for common and rare mutations alike in non–small cell lung cancer has fostered discussions that might have been unthinkable just a decade or so ago.

Cemiplimab/Chemo Represents New Frontline Option for Advanced NSCLC Without Actionable Mutations

October 4th 2021

Miranda Gogishvili, MD, discusses the rationale for examining cemiplimab plus platinum-doublet chemotherapy as a frontline treatment in patients with advanced NSCLC and key findings from the phase 3 EMPOWER-Lung 3 trial.

Adjuvant Atezolizumab Shows Improvement in DFS, Time to Relapse in PD-L1+ Stage II-IIIA NSCLC Subgroups

September 20th 2021

Adjuvant treatment with atezolizumab led to an improvement in disease-free survival and time to locoregional and distant relapse compared with best supportive care in prespecified subgroups of PD-L1–positive patients with stage II to IIIA NSCLC, according to exploratory findings from the phase 3 IMpower010 trial.

Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC

July 31st 2021

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

Frontline I-O Monotherapy Versus Combination Therapy for PD-L1+ Stage IV NSCLC

June 30th 2021

Drs Roy S. Herbst and Sandip P. Patel comment on patient candidacy for immunotherapy as monotherapy to treat PD-L1+ metastatic non–small cell lung cancer versus chemoimmunotherapy.

Frontline Treatment of PD-L1+ Stage IV NSCLC: Cemiplimab

June 30th 2021

Roy S. Herbst, MD, PhD, of Yale Cancer Center, highlights treatment advances in stage IV non–small cell lung cancer, including cemiplimab as frontline monotherapy based on EMPOWER-Lung 1.

ASCO 2021 Updates With Neoadjuvant Immunotherapy in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, cover the latest results with neoadjuvant immunotherapy strategies that were highlighted at the 2021 ASCO Annual Meeting.

4-Year Findings Confirm Long-Term Benefit for Nivo/Ipi in First Line for mNSCLC

June 4th 2021

The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Sugemalimab Shows Prolonged PFS in Stage III NSCLC

May 28th 2021

The investigational PD-L1 inhibitor sugemalimab prolonged progression-free survival in patients with locally advanced, unresectable stage III non–small cell lung cancer without disease progression after concurrent or sequential chemoradiation.

EU Panel Recommends Nivolumab/Ipilimumab in Frontline Unresectable Malignant Pleural Mesothelioma

April 23rd 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the combination of nivolumab and ipilimumab as a frontline treatment for adult patients with unresectable malignant pleural mesothelioma.

The Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer

April 15th 2021

This publication reviews the role of single-agent and dual immunotherapy for the treatment of metastatic non-small-cell lung cancer, recapping key insights from a scientific interchange & workshop.

Neoadjuvant Nivolumab/Chemo Improves pCR in Resectable NSCLC

April 10th 2021

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Dr. Heymach on the Future of Immunotherapy in NSCLC

March 31st 2021

John V. Heymach, MD, PhD, discusses the future of immunotherapy in patients with non–small cell lung cancer.

Durvalumab Use Differs in Real-World, PACIFIC Stage III NSCLC Populations

March 27th 2021

More patients with stage III non–small cell lung cancer received sequential chemoradiation and delayed the time to durvalumab treatment in a real-world setting compared with those enrolled on the phase 3 PACIFIC trial.

Camrelizumab Plus Chemo Prolongs PFS in Advanced Squamous NSCLC

March 25th 2021

First-line treatment with camrelizumab, an investigational PD-1 inhibitor, plus chemotherapy induced robust and durable clinical responses in patients with advanced squamous non–small cell lung cancer.

FDA Will Reassess 6 Immunotherapy Accelerated Approvals

March 12th 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

Rodriguez Relays Insight Into the Integration of Immunotherapy in Lung Cancer

February 18th 2021

In our exclusive interview, Dr. Rodriguez discusses historic treatments in lung cancer that preceded the integration of immunotherapy, shares current treatment selection and sequencing strategies, and forecasts the future of immunotherapy in the field.

Borghaei Breaks Down Choices in Immunotherapy Approaches in Lung Cancer

February 8th 2021

With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.

Dr. Brahmer on Determining When to Start Immunotherapy in Frontline NSCLC

February 8th 2021

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.

Forde Recaps Chemoimmunotherapy Activity in PD-L1–Negative NSCLC

February 8th 2021

Immunotherapy plus chemotherapy is a standard of care for patients with advanced PD-L1–negative non–small cell lung cancer who do not harbor actionable driver mutations.